The largest community of pharma leaders

Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform

HOUSTON–(BUSINESS WIRE)–Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced clinical updates for both the phase 1 GINAKIT2 study of KUR-501 (autologous GD2 CAR-NKT cells) being tested in patients with relapsed/refractory (R/R) neuroblastoma, and the phase 1 ANCHOR study of KUR-502 (off-the-shelf CD19 CAR-NKT cells) being evaluated in patients with R/R CD19 positive malignancies. Compl
Source Read More

Recent Articles